tbuckley/cabot-search huggingface dataset:
Abstract 3973: BRICHOS genes CHM1 and ITM2A maintain an undifferentiated, invasive phenotype in Ewing sarcoma
Authors: Kristina von Heyking, Annette Fasan, Stefan Burdach, Günther H. Richter
Journal: Cancer Research (2014)

Abstract Ewing sarcomas (ES) are highly malignant, osteolytic bone or soft tissue tumors, which are characterized by ews/ets translocations and early metastasis into lung and bone. In this study, we analyzed the role of the BRICHOS domain-containing genes CHM1 and ITM2A in ES pathogenesis, especially in bone-associated tumor growth and metastasis. Both genes are overexpressed in ES and among others appear to be important for chondrogenic differentiation. CHM1 in addition seems directly up-regulated by EWS/FLI1. Using RNA interference, we demonstrate that CHM1 and ITM2A slightly reduced bone invasiveness and osteolysis in vivo that is likely mediated by the suppression of the osteolytic genes HIF1α, IL6, JAG1 and VEGF. Furthermore, CHM1 and ITM2A suppressed the chondrogenic and to a lesser extend the osteogenic differentiation status of ES cells indicating that osteomimicry might play a role in homing, colonizing and invasion into bone tissues. Additionally, we show that both BRICHOS domain-containing genes significantly increased the expression of the stem cell genes, ABCG2 and PROM1. Together with the observed undifferentiated phenotype of ES cells, we demonstrate that CHM1 and ITM2A clearly enhanced lung metastasis in a xenograft mouse model in vivo. Our results suggest that CHM1 and ITM2A are essential players with respect to the undifferentiated phenotype and the metastatic behavior of ES cells. Citation Format: Kristina von Heyking, Annette Fasan, Stefan Burdach, Günther H. Richter. BRICHOS genes CHM1 and ITM2A maintain an undifferentiated, invasive phenotype in Ewing sarcoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3973. doi:10.1158/1538-7445.AM2014-3973
Abstract P2-13-13: Predictors of bilateral mastectomy in breast cancer patients
Authors: Yun Fu, Zhigang Zhuang, Michelle Dewing, Apple Sophia, Chang R Helena
Journal: Cancer Research (2015)

Abstract Background: Breast cancer surgery has experienced an evolutional change from radical mastectomy to conservative techniques due to the migration of stage of disease at diagnosis and adjuvant use of multimodality treatment. While breast conservation is preferred by most, the trend of bilateral mastectomy has been on the rise in the United States. The aim of this study is to determine factors that may affect patients’ choice of bilateral mastectomy. Methods: This is a retrospective study of 376 patients diagnosed with primary invasive breast cancer who were treated by bilateral or unilateral mastectomy (BM or UM) at the Revlon/UCLA Breast Center between Jan. 2002 and Dec. 2010. Patients in the bilateral mastectomy (BM) group were further divided into groups of bilateral mastectomy for bilateral breast cancer and for unilateral breast cancer and contralateral prophylactic mastectomy. Results: When compared with the UM group, the following factors were found to be associated with the BM: younger age (p&amp;lt;0.001), pre-menopause (p&amp;lt;0.001), having a family history of breast cancer (p&amp;lt;0.001) or ovarian cancer (p=0.017), BRCA 1 and 2 mutations (p&amp;lt;0.001, p=0.011, respectively), more breast biopsies (p=0.007), history of breast augmentation (p=0.014), more MRI study within 6 months before the surgery (p=0.029), more likely to have reconstruction surgery (p&amp;lt;0.001) and sentinel lymph node biopsy (SLNB) (p&amp;lt;0.001). Multivariate analysis indicated that patients with smaller tumor size (p&amp;lt;0.001, OR 0.087), negative nodes (p&amp;lt;0.001), sentinel lymph node biopsy as nodal surgery (p&amp;lt;0.001, OR 0.259), BRCA mutation (p=0.020, OR 6.537) and positive family history (p=0.001, OR 2.732) were more likely to choose bilateral mastectomy with reconstruction using tissue expanders or implants (p&amp;lt;0.001, OR 4.546). Conclusion: Bilateral mastectomy is associated with lower TN stage, requiring only SNLB, presence of BRCA mutation and/or high risk family history. Tissue expanders or implants based reconstructions were more frequently chosen by patients with bilateral mastectomy. Citation Format: Yun Fu, Zhigang Zhuang, Michelle Dewing, Apple Sophia, Chang R Helena. Predictors of bilateral mastectomy in breast cancer patients [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-13-13.
The Ig Heavy Chain 3′ End Confers a Posttranscriptional Processing Advantage to Bcl-2–IgH Fusion RNA in t(14;18) Lymphoma
Authors: Alexander Scheidel Petrovic, Robert L. Young, Bernadette Hilgarth, Peter Ambros, Stanley J. Korsmeyer, Ulrich Jaeger
Journal: Blood (1998)
SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma
Authors: G. Blumberga, L. Groes, R. Dahl
Journal: Allergy (2010)

To cite this article: Blumberga G, Groes L, Dahl R. SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma. Allergy 2011; 66: 178–185. Background: Specific immunotherapy is the only treatment with the potential to prevent progression of the allergic disease and the potential to cure patients. The immunomodulatory ability of SQ-standardized house dust mite (HDM) subcutaneous immunotherapy (SCIT) was investigated in patients with allergic asthma. Methods: Fifty-four adults with HDM-allergic asthma were randomized 1 : 1 to receive SQ-standardized HDM SCIT (ALK) or placebo for 3 years. At baseline, and after 1, 2 and 3 years of treatment, the lowest possible inhaled corticosteroid dose required to maintain asthma control was determined, followed by determinations of nonspecific and HDM-allergen-specific bronchial hyperresponsiveness, late asthmatic reaction (LAR), immediate and late-phase skin reactions, and immunological response. Results: SQ-standardized HDM SCIT provided a statistically significantly higher HDM-allergen tolerance (P < 0.05 vs placebo) in terms of a 1.6-fold increase in PD20 (HDM-allergen inhalation challenge), a 60-fold increase in skin test histamine equivalent HDM-allergen concentrations, reduced immediate- and reduced or abolished late-phase skin reactions, as well as fewer patients with LAR. PD20 (methacholine inhalation challenge) increased initially and was similar between groups. House dust mite SCIT induced an initial increase in serum HDM-allergen-specific IgE (P = 0.028 vs placebo), which then declined to baseline value. House dust mite SCIT induced an increase in components blocking IgE binding to allergen [ΔIgE-blocking factor: 0.31; 95% CI of (0.26; 0.37)] after 1 year that remained constant after 2 and 3 years (P < 0.0001 vs placebo). Conclusion: SQ-standardized HDM SCIT induced a consistent immunomodulatory effect in adults with HDM-allergic asthma; the humoral immune response was changed and the HDM-allergen tolerance in lung and skin increased.
A User-Centered Design Approach to Information Sharing for Older Patients and Their Families
Authors: Pravene A. Nath, Christopher D. Sharp
Journal: JAMA Internal Medicine (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
Authors: H Wu, C Hu, A Wang, E L Weisberg, W Wang, C Chen, Z Zhao, K Yu, J Liu, J Wu, A Nonami, L Wang, B Wang, R M Stone, S Liu, J D Griffin, J Liu, Q Liu
Journal: Leukemia (2015)
Clinical microbiological case: a 35-year-old HIV-positive man with intermittent fever and chronic diarrhea
Authors: F.-C. Bange, S. Ruttkowski, M. Kist, S. Bereswill, D. Meyer, R.E. Schmidt, H. Tillmann, I. Schedel, M.P. Manns, F. Gunzer
Journal: Clinical Microbiology and Infection (2000)
Abstract 11217: A New Treatment for Diastolic Heart Failure: Trabecular Cutting
Authors: David L Halaney, Pedro J Acevedo, William Pérez, Marc D Feldman
Journal: Circulation (2014)

Background: Heart failure with preserved ejection fraction remains a leading cause of hospitalization, without development of new medications and operative procedures to treat these patients. We hypothesize that trabeculae carneae serve an important role in modulating LV diastolic compliance, and during hypertrophy of the myocardium, trabeculae contribute to abnormal compliance. Methods and Results: Eight ex vivo human hearts from patients with LV diastolic dysfunction were perfused at 37[[Unable to Display Character: &amp;#8304;]]C and had a balloon inserted into the LV through the mitral annulus. Diastolic LV pressure-volume compliance curves were measured at baseline and following trabecular cutting. LV compliance improved significantly (n=6, p&lt;0.001), but not in the control hearts without trabecular cutting (n=2, p=0.85). The figure shows aggregate data from the six hearts before and after trabecular cutting. To determine if trabeculae serve a similar role in all mammals, 28 hearts from 10 species were obtained. We demonstrate significant relationships between circumferential wall stress and the number of trabeculae in these species, particularly trabeculae which attach nets of trabeculae to the ventricle walls (p=0.02, n=733) and trabeculae located at the apex and free wall (p=0.02, n=602). The percent of LV cardiac titin of the stiff isoform (%N2B), a determinate of LV diastolic compliance, also demonstrated a significant relationship with the number of trabeculae with the same anatomic subsets (p=0.04, n=597; and p=0.02, n=488, respectively). Conclusions: We demonstrate for the first time that rather than being an embryologic remnant, trabeculae carneae serve an important role in the maintenance of passive LV diastolic compliance, and can contribute to LV diastolic dysfunction. A new procedure, cutting trabeculae, is proposed to improve LV diastolic compliance.
Abstract 1572: Dystrophin Is a tumor suppressor in human cancers with myogenic programs
Authors: Yuexiang Wang, Adrian Marino-Enriquez, Richard Bennett, Meijun Zhu, Grant Eilers, Cristina Antonescu, Christopher Fletche, Chandrajit Raut, Matt van de Rijn, Louis Kunkel, George Demetri, Jonathan Fletcher
Journal: Cancer Research (2014)

Abstract Many common human mesenchymal tumors, including gastrointestinal stromal tumor (GIST), rhabdomyosarcoma (RMS), and leiomyosarcoma (LMS), feature myogenic differentiation. Although presumptive initiating mutations have been identified in these cancers, the subsequent mechanisms of malignant progression are not known. Here we report that intragenic deletion of the dystrophin-encoding and muscular dystrophy-associated DMD gene is a frequent mechanism by which myogenic tumors progress to high-grade, lethal sarcomas. Genome-wide SNP screens demonstrated DMD intragenic deletions in 23 of 38 myogenic sarcomas (61%) compared to 0 of 58 non-myogenic sarcomas (p &amp;lt; 0.0001). Although DMD is an X-linked gene, somatic DMD deletions affected both sexes equally and DMD deletions in female patients involved the active X chromosome, resulting in functional DMD nullisomy. Dystrophin was expressed strongly in nonneoplastic and benign counterparts for GIST, RMS and LMS, and the DMD deletions in the malignant myogenic sarcomas clustered at the 5′ end of the gene, inactivating larger dystrophin isoforms, including 427kDa dystrophin, while preserving expression of an essential 71kDa isoform (Dp71) which is encoded by the DMD 3′ end. Dystrophin restoration inhibited myogenic sarcoma cell migration, invasion, anchorage independence, and invadopodia formation, and dystrophin inactivation was found in 96%, 100%, and 62% of metastatic GIST, embryonal RMS, and LMS, respectively. The genomic, clinicopathological and functional evidence validate dystrophin as a tumor suppressor and likely anti-metastatic factor, suggesting that therapies in development for muscular dystrophies may also have relevance in treatment of cancer. Citation Format: Yuexiang Wang, Adrian Marino-Enriquez, Richard Bennett, Meijun Zhu, Grant Eilers, Cristina Antonescu, Christopher Fletche, Chandrajit Raut, Matt van de Rijn, Louis Kunkel, George Demetri, Jonathan Fletcher. Dystrophin Is a tumor suppressor in human cancers with myogenic programs. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1572. doi:10.1158/1538-7445.AM2014-1572
Health‐related quality of life of food allergic patients measured with generic and disease‐specific questionnaires
Authors: B. M. J. Flokstra‐de Blok, J. L. Van Der Velde, B. J. Vlieg‐Boerstra, J. N. G. Oude Elberink, A. DunnGalvin, J. O’B. Hourihane, E. J. Duiverman, A. E. J. Dubois
Journal: Allergy (2010)

Health-related quality of life (HRQL) has never been measured with both generic and disease-specific questionnaires in the same group of food allergic patients. The aim of this study was to compare HRQL of food allergic patients as measured with generic and disease-specific questionnaires.Generic questionnaires (CHQ-CF87 and RAND-36) and disease-specific HRQL questionnaires (FAQLQ-CF, -TF and -AF) were completed by 79 children, 74 adolescents and 72 adults with food allergy. Floor and ceiling effects, percentage of agreement and multivariate stepwise regression analysis were used to compare the generic and disease-specific measurements.The Food Allergy Quality of Life Questionnaires (FAQLQs) showed minimal floor or ceiling effects. The CHQ-CF87 and RAND-36 showed minimal floor effects, but remarkable ceiling effects (> 73%) were found for the scales role functioning-emotional (RE), role functioning-behaviour (RB), role functioning-physical (RP) in children and adolescents and the scale RE (> 79%) in adults. Additionally, we found low percentages of agreement between the generic and disease-specific questionnaires to identify the same food allergic patients with the best or worst HRQL. Only patients with the best disease-specific HRQL also tended to have the best generic HRQL. Finally, the explained variance in HRQL by patient characteristics was higher in the disease-specific questionnaires (30.7-62.8%) than in the generic scales (6.7-31.7%).Disease-specific HRQL questionnaires may be more suitable to measure clinically important impairments in HRQL or HRQL differences over time in food allergic patients. However, generic HRQL questionnaires are indispensable for the comparison between different diseases and are thus complementary.
Alcohol-attributable deaths and years of potential life lost among American Indians and Alaska Natives--United States, 2001--2005
Authors: Timothy S. Naimi, N. Cobb, D. Boyd, Dwayne W. Jarman, Robert Brewer, David E. Nelson, J. Holt, D Espey, P Snesrud, P Chavez
Journal: MMWR Morbidity and Mortality Weekly Report (2008)
Viral hepatitis among men who have sex with men, epidemiology and public health consequences
Authors: A T Urbanus, R van Houdt, T JW van de Laar, R  A Coutinho
Journal: Eurosurveillance (2009)

Viral hepatitis causes major disease burden worldwide, due to the chronic hepatitis sequelae: cirrhosis and primary liver cancer. Transmission of viral hepatitis is a problem not only in low-income countries, but also in high-income ones where viral hepatitis is a frequently occurring infection among men who have sex with men (MSM). Although the transmission routes of the three main hepatitis viruses, A, B and C, differ, MSM mainly acquire viral hepatitis during sexual contact. Vaccination programmes (only available for hepatitis A and B), raising awareness, and screening can be used to prevent transmission. However, despite the introduction of such methods in many high-income countries, the spread of viral hepatitis among MSM is still ongoing. This paper provides an overview of sexually acquired hepatitis A, B, and C among MSM in high-income countries, using recent insights obtained through molecular epidemiology, with the aim to raise awareness, improve vaccination coverage, and stimulate prevention programs.
MRI to Evaluate Left Atrial and Ventricular Reverse Remodeling After Restrictive Mitral Annuloplasty in Dilated Cardiomyopathy
Authors: Jos J.M. Westenberg, Rob J. van der Geest, Hildo J. Lamb, Michel I.M. Versteegh, Jerry Braun, Joost Doornbos, Albert de Roos, Ernst E. van der Wall, Robert A.E. Dion, Johan H.C. Reiber, Jeroen J. Bax
Journal: Circulation (2005)

Background— Data on reverse remodeling of the left atrium (LA) and left ventricle (LV) after restrictive annuloplasty in patients with dilated cardiomyopathy are scarce, and follow-up studies are performed with echocardiography. Methods and Results— Twenty patients with dilated cardiomyopathy and severe mitral regurgitation selected for restrictive mitral annuloplasty underwent serial MRI studies (within 1 week before surgery, and 2 months [n =18] and 1 year [n =13] after surgery). Early mortality was 10%; all patients were free from endocarditis and thromboembolism. New York Heart Association class improved from 3.2±0.4 to 1.2±0.9. Only 1 patient developed recurrent severe mitral regurgitation during follow-up and it was re-repaired. LA end-systolic volumes decreased significantly over time (from 165±48 mL to 109±23 mL to 111±28 mL; P &lt;0.01), as did LA end-diastolic volumes (from 92±32 mL to 71±22 mL to 75±17 mL; P =0.01). LV end-diastolic volumes decreased significantly (from 244±56 mL to 184±54 mL to 195±67 mL; P &lt;0.01), whereas end-systolic volumes did not change significantly. LV ejection fraction increased significantly (from 35±8% to 46±13% to 46±15%; P &lt;0.01) and LV mass decreased significantly (from 150±43 grams to 132±39 grams to 136±33 grams; P =0.02). Conclusion— Restrictive annuloplasty in patients with dilated cardiomyopathy yielded excellent clinical results associated with significant LA and LV reverse remodeling over time as demonstrated by MRI.
Abstract 3721: ALK inactivation induced acquired resistance to alectinib in lung cancer harboring EML4-ALK fusion gene
Authors: Hideko Isozaki, Eiki Ichihara, Masayuki Yasugi, Ochi Nobuaki, Katsuyuki Hotta, Nagio Takigawa, Toshiaki Sendo, Mitsune Tanimoto, Katsuyuki Kiura
Journal: Cancer Research (2014)

Abstract Dramatic clinical responses to a first generation anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (TKI) crizotinib have been observed in patients with advanced non-small cell lung cancer (NSCLC) haboring ALK fusion gene. Alectinib (CH5424802) (Chugai Pharmaceutical Co., Ltd.) is a second generation ALK-TKI could partially overcome acquired resistance to crizotinib in vitro (Cancer Cell 19, 2011: 679-90), and showed promising result in phase I/II clinical trials with high response rate (93.5 %) and less toxicity than crizotinib. However, even this promising ALK-TKI, the problem of acquired resistance is inevitable. To elucidate resistant mechanisms, we established an alectinib-resistant cell line H2228/CHR from H2228 that have echinoderm microtubule associated protein like 4 (EML4)-ALK fusion gene, by continuous exposure to this agent. ALK fusion gene disappeared in H2228/CHR, which was confirmed Western blotting, IHC, qRT-PCR and FISH. H2228/CHR cells presented higher phosphorylated levels of epidermal growth factor receptor (EGFR) than the parental H2228 cells and became more sensitive to EGFR-TKI erlotinib. Next, we established alectinib-resistant ABC-11/CHR cells from ABC-11, a cell line established from pleural effusion of EML4-ALK positive ALK-TKI naïve patient. In ABC-11/CHR cells, phosphorylated levels of ALK was markedly decreased and phosphorylated levels of MET was increased.In addition, autocrine of HGF was increased in ABC-11/CHR cells. ABC-11/CHR showed sensitivity to ALK/MET tyrosine kinase inhibitor, crizotinib in vitro and in vivo model. In conclusion, inactivation of ALK signaling induced acquired resistance to alectinib in NSCLC harboring ALK fusion gene. Signaling switch from ALK to EGFR or MET was observed in the alectinib-resistant cells. We revealed to overcome such acquired resistance using erlotinib or crizotinib. Citation Format: Hideko Isozaki, Eiki Ichihara, Masayuki Yasugi, Ochi Nobuaki, Katsuyuki Hotta, Nagio Takigawa, Toshiaki Sendo, Mitsune Tanimoto, Katsuyuki Kiura. ALK inactivation induced acquired resistance to alectinib in lung cancer harboring EML4-ALK fusion gene. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3721. doi:10.1158/1538-7445.AM2014-3721
Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Ophthalmic findingsSST report no. 11
Authors: Barbara S Hawkins, Neil M Bressler, Päivi H Miskala, Susan B Bressler, Nancy M Holekamp, Marta J Marsh, Maryann Redford, Steven D Schwartz, Paul Sternberg, Matthew A Thomas, David J Wilson
Journal: Ophthalmology (2004)